MCID: OVR049
MIFTS: 56

Ovarian Disease malady

Categories: Endocrine diseases, Reproductive diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Ovarian Disease

Aliases & Descriptions for Ovarian Disease:

Name: Ovarian Disease 12 14
Ovarian Dysfunction 12 52 14
Ovarian Diseases 52 42 69
Disorder of Endocrine Ovary 69
Ovarian Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:1100 DOID:1414
MeSH 42 D010049
NCIt 47 C26841
ICD9CM 35 256.3 256.39
ICD10 33 E28 E28.3 E28.9

Summaries for Ovarian Disease

MedlinePlus : 41 the ovaries are part of the female reproductive system. women have two ovaries, one on each side of the uterus. each ovary is about the size and shape of an almond. the ovaries produce and store a woman's eggs. during ovulation, an ovary releases an egg. if that egg is fertilized by a sperm, a pregnancy can occur. ovaries also make the female hormones estrogen and progesterone. when a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. problems with the ovaries include ovarian cancer ovarian cysts and polycystic ovary syndrome premature ovarian failure ovarian torsion, a twisting of the ovary

MalaCards based summary : Ovarian Disease, also known as ovarian dysfunction, is related to endometriosis and mullerian aplasia and hyperandrogenism, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Prolactin Signaling Pathway and Peptide hormone metabolism. The drugs Metformin and Ganirelix have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and pituitary, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 71 Ovarian diseases can be classified as endocrine disorders or as a disorders of the reproductive... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Ovarian Insufficiency, Familial Fmr1-Related Primary Ovarian Insufficiency
Ovarian Insufficiency Due to Fsh Resistance

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 endometriosis 29.3 GNRH1 PRL
2 mullerian aplasia and hyperandrogenism 11.0
3 leukoencephalopathy with vanishing white matter 10.8
4 polycystic ovary syndrome 10.6
5 premature ovarian failure 10.6
6 diabetes mellitus, insulin-dependent, 2 10.3 IGFBP1 INS SHBG
7 vertebral artery occlusion 10.3 GNRH1 INS PRL
8 dacryoadenitis 10.3 IGF1 INS PRL
9 olfactory nerve neoplasm 10.3 GNRH1 INS PRL
10 protein s deficiency 10.3 IGF1 INS PRL
11 glioblastoma mesenchymal subtype 10.3 CYP19A1 PRL SHBG
12 african histoplasmosis 10.3 GNRH1 PRL
13 seow najjar syndrome 10.3 IGF1 INS
14 polyneuropathy 10.3 CYP19A1 SHBG
15 adams-oliver syndrome 6 10.3 CYP19A1 GNRH1 INS
16 diencephalic neoplasm 10.3 GNRH1 INS PRL
17 deafness, autosomal recessive 74 10.3 CYP19A1 GNRH1 IGF1
18 adrenal cortical adenocarcinoma 10.3 GNRH1 INS PRL
19 leydig cell hypoplasia with pseudohermaphroditism 10.3 CYP19A1 FSHR
20 merkel cell carcinoma 10.3 INS PRL REN
21 congenital articular rigidity 10.3 CGA CYP19A1 SHBG
22 cervix squamous papilloma 10.2 IGF1 INS PRL
23 renal-hepatic-pancreatic dysplasia 10.2 CGA GNRH1 IGF1
24 hypospadias 1, x-linked 10.2 CGA CYP19A1 SHBG
25 bile acid synthesis defect, congenital, 4 10.2 GNRH1 IGF1 PRL
26 fatty liver disease 10.2 INS PRL REN
27 immune system organ benign neoplasm 10.2 IGF1 PRL REN
28 extrahepatic bile duct adenocarcinoma 10.2 IGF1 IGFBP1 SHBG
29 aflatoxins-related hepatocellular carcinoma 10.2 IGF1 INS PRL SHBG
30 limb ischemia 10.2 IGF1 INS REN
31 necrobiosis lipoidica 10.2 IGF1 PRL SHBG
32 exostosis 10.2 IGF1 IGFBP1 INS SHBG
33 diabetic encephalopathy 10.2 IGF1 INS REN
34 urethra clear cell adenocarcinoma 10.2 GNRH1 IGF1 INS PRL
35 endocrine organ benign neoplasm 10.2 IGF1 PRL REN
36 papillary craniopharyngioma 10.2 GNRH1 IGF1 INS PRL
37 blind loop syndrome 10.2 IGF1 IGFBP1 INS SHBG
38 thrombophilia 10.2 IGF1 IGFBP1 INS PRL
39 glomangiomyoma 10.2 CGA INS PRL SHBG
40 dystonia-parkinsonism, x-linked 10.2 CYP19A1 SHBG
41 haverhill fever 10.2 CYP19A1 GNRH1 IGF1 PRL
42 vestibular gland benign neoplasm 10.2 IGF1 INS PRL REN
43 astroblastoma 10.2 GNRH1 PRL REN SHBG
44 capillary disease 10.2 CGA CYP19A1 PRL SHBG
45 acute thyroiditis 10.2 CYP19A1 FSHR PRL SHBG
46 dientamoebiasis 10.2 CYP19A1 REN
47 adult medulloblastoma 10.2 GNRH1 IGF1 SHBG
48 adrenal adenoma 10.2 IGF1 INS SHBG
49 edict syndrome 10.2 IGF1 IGFBP1 INS PRL SHBG
50 body dysmorphic disorder 10.1 IGF1 INS PRL REN SHBG

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain, mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 FMR1 FOXL2 FSHR GDF9 GNRH1 IGF1
2 homeostasis/metabolism MP:0005376 9.73 AMH CGA CYP19A1 FOXL2 FSHR GALT
3 reproductive system MP:0005389 9.5 AMH BMP15 CGA CYP19A1 FMR1 FOXL2

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 808)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
2
Ganirelix Approved Phase 4,Phase 3,Phase 2,Early Phase 1 123246-29-7, 124904-93-4 25081094
3
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
4
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
7
Orlistat Approved, Investigational Phase 4,Phase 3,Phase 2 96829-58-2 3034010
8
Ezetimibe Approved Phase 4 163222-33-1 150311
9
Cetrorelix Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120287-85-6 16129715 25074887
10
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
11
Nicotine Approved Phase 4 54-11-5 942 89594
12
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
13
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
14
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2 53714-56-0 3911 657181
15
Buserelin Approved Phase 4,Phase 3 57982-77-1
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
17
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
18
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
20
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
21
Zinc Approved Phase 4,Early Phase 1 7440-66-6 32051 23994
22
Levonorgestrel Approved, Investigational Phase 4,Phase 2,Phase 1 797-63-7, 17489-40-6 13109
23
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
24
Goserelin Approved Phase 4,Phase 3,Phase 2 65807-02-5 47725 5311128
25
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
26
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
27
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
28
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
29
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
30
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
31
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
32
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71-58-9
33
Menotropins Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 61489-71-2 5360545
34
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
35
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 616-91-1 12035
36
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
37
Tranexamic Acid Approved Phase 4 1197-18-8 5526
38
Liraglutide Approved Phase 4 204656-20-2
39
Norethindrone Approved Phase 4,Phase 2,Phase 3,Early Phase 1 68-22-4 6230
40
Danazol Approved Phase 4 17230-88-5 28417
41
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
42
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
43
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
44
Citalopram Approved Phase 4 59729-33-8 2771
45
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
46 Moxonidine Approved Phase 4 75438-57-2 4810
47
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Alogliptin Approved Phase 4 850649-61-5 11450633
50
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290

Interventional clinical trials:

(show top 50) (show all 3311)
id Name Status NCT ID Phase
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Unknown status NCT01815138 Phase 4
3 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
4 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
5 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
6 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4
7 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
8 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
9 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4
10 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4
11 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4
12 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
13 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4
14 Ovarian Tissue Freezing For Fertility Preservation Unknown status NCT00902720 Phase 4
15 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4
16 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
17 Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain Unknown status NCT00844012 Phase 4
18 Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation Unknown status NCT00417183 Phase 4
19 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
20 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4
21 Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF Unknown status NCT02201914 Phase 4
22 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4
23 Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates Unknown status NCT01237535 Phase 4
24 Ovarian Stimulation: Inositol and Melatonin Unknown status NCT01267604 Phase 4
25 Corifollitropin Alfa Versus Follitropin Beta in High Responders Unknown status NCT02471677 Phase 4
26 The Effect of LH-Priming During Early Follicular Phase in IVF Treatment. Unknown status NCT00334425 Phase 4
27 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4
28 Intrauterine Insemination and Luteal Fase Support Unknown status NCT01826747 Phase 4
29 Study of Dual Trigger Ovulation in Oocyte Donors Unknown status NCT01443546 Phase 4
30 Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF Unknown status NCT02070198 Phase 4
31 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4
32 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4
33 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4
34 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4
35 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4
36 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4
37 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4
38 Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH Completed NCT00417157 Phase 4
39 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4
40 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed NCT01999569 Phase 4
41 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
42 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4
43 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
44 Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
45 The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst Completed NCT00713778 Phase 4
46 A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve Completed NCT00746278 Phase 4
47 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4
48 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4
49 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4
50 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

MalaCards organs/tissues related to Ovarian Disease:

39
Ovary, Uterus, Pituitary, Testes, T Cells, Monocytes, Nk Cells

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 417)
id Title Authors Year
1
Polycystic ovarian disease and associated factors. ( 27075885 )
2016
2
Role of Glucocorticoids in Cystic Ovarian Disease: Expression of Glucocorticoid Receptor in the Bovine Ovary. ( 26677854 )
2016
3
A novel method of extraction of bamboo seed oil (Bambusa bambos Druce) and its promising effect on metabolic symptoms of experimentally induced polycystic ovarian disease. ( 27127318 )
2016
4
BMP2, 4 and 6 and BMPR1B are altered from early stages of bovine cystic ovarian disease development. ( 27486268 )
2016
5
Bidirectional Estrogen-Like Effects of Genistein on Murine Experimental Autoimmune Ovarian Disease. ( 27834809 )
2016
6
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. ( 26657509 )
2016
7
Involvement of Matrix Metalloproteinases and their Inhibitors in Bovine Cystic Ovarian Disease. ( 27993358 )
2016
8
Molecular aspects of bovine cystic ovarian disease pathogenesis. ( 25767139 )
2015
9
Altered Expression of Pro-inflammatory Cytokines in Ovarian Follicles of Cows with Cystic Ovarian Disease. ( 26065705 )
2015
10
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle. ( 26031184 )
2015
11
Impaired insulin signaling pathway in ovarian follicles of cows with cystic ovarian disease. ( 25813700 )
2015
12
Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687660 )
2015
13
"Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687659 )
2015
14
Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. ( 25878392 )
2015
15
A novel serum microRNA panel to discriminate benign from malignant ovarian disease. ( 25451316 )
2015
16
Altered expression of transforming growth factor-beta isoforms in bovine cystic ovarian disease. ( 25112788 )
2014
17
Polycystic ovarian disease: still an enigma! ( 24685855 )
2014
18
GC-MS analysis of Cocus nucifera flower extract and its effects on heterogeneous symptoms of polycystic ovarian disease in female Wistar rats. ( 25263979 )
2014
19
Can treatment for polycystic ovarian disease induce ovarian tumour? A case report. ( 24596770 )
2014
20
Role of activin, inhibin, and follistatin in the pathogenesis of bovine cystic ovarian disease. ( 25001504 )
2014
21
Epidemiological description of cystic ovarian disease in argentine dairy herds: risk factors and effects on the reproductive performance of lactating cows. ( 25292292 )
2014
22
Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling. ( 24576485 )
2014
23
Cutting edge: Ly49C/Ia8> neonatal NK cells predispose newborns to autoimmune ovarian disease induced by maternal autoantibody. ( 23960238 )
2013
24
Changes in the expression of Heat Shock Proteins in ovaries from bovines with cystic ovarian disease induced by ACTH. ( 23937990 )
2013
25
Interaction between IGF1 and IGFBPs in bovine cystic ovarian disease. ( 23693122 )
2013
26
Adrenal ganglioneuroma in a patient with polycystic ovarian disease (PCOD): a rare association. ( 24145507 )
2013
27
Ovarian localization of 11I^-hydroxysteroid dehydrogenase (11I^HSD): effects of ACTH stimulation and its relationship with bovine cystic ovarian disease. ( 23972491 )
2013
28
Assisted reproduction in polycystic ovarian disease: A multicentric trial in India. ( 23869152 )
2013
29
Environmental toxicants induce ovarian disease across generations. ( 23275984 )
2012
30
Effect of shatapushpa taila matra basti and pathadi kwatha on poly cystic ovarian disease. ( 23559797 )
2012
31
Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective. ( 22028409 )
2012
32
Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum. ( 23188839 )
2012
33
Doppler imaging in the diagnosis of ovarian disease. ( 23480621 )
2012
34
Environmentally induced epigenetic transgenerational inheritance of ovarian disease. ( 22570695 )
2012
35
Steroid receptor mRNA expression in the ovarian follicles of cows with cystic ovarian disease. ( 21536311 )
2012
36
Tolerogenic DNA vaccine for prevention of autoimmune ovarian disease. ( 22221010 )
2012
37
Management of ovarian disease in pregnancy. ( 22115171 )
2011
38
Influence of insulin-like growth factor-binding proteins-2 and -3 in the pathogenesis of cystic ovarian disease in cattle. ( 21940120 )
2011
39
A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder. ( 22295263 )
2011
40
Cell proliferation and survival mechanisms underlying the abnormal persistence of follicular cysts in bovines with cystic ovarian disease induced by ACTH. ( 20800980 )
2010
41
Heat shock protein patterns in the bovine ovary and relation with cystic ovarian disease. ( 19744807 )
2010
42
Risk factors associated with cystic ovarian disease in Norwegian dairy cattle. ( 21059258 )
2010
43
Insulin-like growth factor-II and insulin-like growth factor-binding proteins in bovine cystic ovarian disease. ( 19959179 )
2010
44
Surgical management of ovarian disease in infants, children, and adolescents: a 15-year review. ( 20059326 )
2010
45
A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate. ( 19956961 )
2010
46
Leptin concentrations in the peritoneal fluid of women with ovarian endometriosis are different according to the presence of a 'deep' or 'superficial' ovarian disease. ( 19544117 )
2009
47
Prospective identification and characterization of ovarian cancer stem cells: Implications for the treatment of chemotherapy resistant/recurrent ovarian disease. ( 19158501 )
2009
48
Efficacy of intravaginal progesterone administration combined with prostaglandin f(2alpha) for cystic ovarian disease in Japanese Black cows. ( 18981664 )
2008
49
Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells. ( 18452236 )
2008
50
Polycystic ovarian disease unmasked by pulsatile GnRH therapy in a subgroup of women with hypothalamic amenorrhea. ( 17583701 )
2008

Variations for Ovarian Disease

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 AMH BMP15 GDF9 GNRH1 IGF1 IGFBP1
2 extracellular region GO:0005576 9.47 AMH BMP15 CGA GDF9 GNRH1 IGF1
3 secretory granule GO:0030141 9.33 PRL ZP1 ZP3
4 endosome lumen GO:0031904 9.26 INS PRL

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 CGA GDF9 IGF1 INS PRL
2 cell-cell signaling GO:0007267 9.89 AMH CGA GNRH1 INS
3 cellular protein metabolic process GO:0044267 9.77 BMP15 IGF1 IGFBP1 INS PRL
4 BMP signaling pathway GO:0030509 9.73 AMH BMP15 GDF9
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 FSHR IGF1 INS
6 binding of sperm to zona pellucida GO:0007339 9.65 ZP1 ZP3 ZP4
7 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 INS
8 protein kinase C signaling GO:0070528 9.58 ZP3 ZP4
9 female gonad development GO:0008585 9.58 CYP19A1 FOXL2 FSHR
10 positive regulation of glycolytic process GO:0045821 9.57 IGF1 INS
11 single fertilization GO:0007338 9.56 FOXL2 ZP1 ZP3 ZP4
12 ovulation cycle GO:0042698 9.54 GNRH1 PRL
13 positive regulation of acrosome reaction GO:2000344 9.52 ZP3 ZP4
14 female gamete generation GO:0007292 9.5 BMP15 FSHR GDF9
15 negative regulation of binding of sperm to zona pellucida GO:2000360 9.49 ZP3 ZP4
16 oocyte growth GO:0001555 9.46 FOXL2 GDF9
17 positive regulation of humoral immune response GO:0002922 9.43 ZP3 ZP4
18 uterus development GO:0060065 9.33 CYP19A1 FOXL2 FSHR
19 gonad development GO:0008406 9.13 AMH CGA FSHR
20 regulation of MAPK cascade GO:0043408 8.92 BMP15 FSHR GDF9 REN

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 AMH BMP15 GDF9 IGF1
2 transforming growth factor beta receptor binding GO:0005160 9.33 AMH BMP15 GDF9
3 acrosin binding GO:0032190 9.26 ZP3 ZP4
4 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS REN
5 hormone activity GO:0005179 9.1 AMH CGA GNRH1 IGF1 INS PRL

Sources for Ovarian Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....